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SYNOPSIS 41 
Objectives 42 
Our primary aim was to study Diabetes Mellitus (DM) arising during combination Antiretroviral 43 
Therapy (cART), and to attempt to identify associations between these cases, and triglycerides (TRG) 44 
and triglycerides to high-density lipoprotein cholesterol ratio (TRG/HDL).  Our secondary aim was to 45 
analyze the association between DM development and Hepatic fibrosis. 46 
Methods 47 
A retrospective cohort study. Patients from the ICONA Foundation study initiating first-line cART 48 
between 1997 and 2013 were selected and observed until new-onset DM or most recent clinical follow-49 
up. The predictive value of TRG and TRG/HDL ratio levels on DM was evaluated using multivariable 50 
Poisson regression models. 51 
Results  52 
3,546 patients [males 73.7%, median age 38-yrs; median BMI 23.1; Hepatitis C antibody positive 53 
22.1%] were included. Of these, 80 developed DM over 13,911 PYFU, corresponding to 5.7 cases per 54 
1,000 patient-years of follow-up (95% CI4.6-7.1). At Multivariable analysis, latest TRG/HDL, when 55 
high, was associated with significant increases in DM risk (rate ratio [RR] 1.63; 95% CI 1.32-2.01 per 56 
10 points higher), while current TRG, in contrast, was associated with new-onset DM only at crude 57 
analysis. Advanced liver fibrosis (defined as FIB-4 index >3.25) was also shown to be an independent 58 
risk factor for DM (RR 2.91; 95% CI 1.10-7.72).  59 
Conclusions 60 
High TRG/HDL ratio predicted risk of new-onset DM, independently of other traditional risk factors.  61 
Furthermore, our findings suggest that advanced hepatic fibrosis, estimated using FIB-4 score, could 62 
provide an additional predictor for DM. 63 
 64 
 65 
  
INTRODUCTION 66 
Combination Antiretroviral Therapy (cART) has dramatically reduced morbidity and mortality in 67 
HIV-infected patients, prolonging their life expectancy.1 At the same time, ageing and related co-68 
morbidities represent serious challenges in this population. The incidence of co-morbidities associated 69 
with ageing appears to be much higher, and to occur earlier, in HIV-infected individuals with respect 70 
to their HIV-uninfected counterparts.2 71 
 72 
Increased risk of diabetes mellitus (DM) in HIV–infected subjects is a matter of debate. Whilst an 73 
association between HIV infection and heightened risk of diabetes has been demonstrated in some 74 
studies, 3-5 other researches have failed to support such findings.6-8 75 
 76 
Dyslipidemia is a common feature among HIV-infected patients, particularly during cART. According 77 
to the American Diabetes Association, all overweight patients whose high density lipoproteins-78 
cholesterol (HDL-c) are less than 35 mg/dl (0.9 mmol/l) and whose triglycerides (TRG) are higher 79 
than 250 mg/dl (2.8 mmol/l) should undergo testing for diabetes.9 Moreover, ratio between TRG and 80 
HDL-c levels (TRG/HDL) has been cited as a marker of insulin resistance, which is the most important 81 
risk factor for developing DM.10-12  82 
 83 
Although high TRG and low HDL-c are frequently found in HIV-infected patients on cART,13 they 84 
are not always associated with obesity.  This is because HIV-infected patients often have lower body 85 
mass indexes (BMI) compared to the general population.14 In addition, the relationship between HDL-86 
c and TRG plasma levels has been postulated to be different in patients with HIV-related, with respect 87 
to non-HIV-related dyslipidemia.15  Finally, cART introduction heavily alters the lipid profile within 88 
the HIV-infected population.16  89 
Hence, the predictive roles of TRG, HDL-c and TRG/HDL in development of DM are not well 90 
estabilished in HIV-infected patients, since it is unclear whether abnormalities in these levels are 91 
associated with DM, or are merely side effects of cART which have little impact on DM onset.  This 92 
question merits further evaluation. 93 
 94 
Our primary aim was to verify the association between TRG and TRG/HDL ratio and Diabetes’ onset. 95 
Our secondary objective was to evaluate associations between DM and liver fibrosis during cART, 96 
given the known association between Insulin Resistance and non-alcoholic fatty liver disease 97 
(NAFLD).17,18  98 
  
 99 
METHODS 100 
 101 
The Icona Foundation Study is a cohort of HIV-infected patients, which superseded the original Italian 102 
Cohort of Antiretroviral-Naive Patients study, (detailed description of this cohort elsewhere),19 103 
recruiting HIV-positive naïve patients. CD4+ cell counts and viral load are measured at least every 6 104 
months, as are other laboratory parameters, as well as clinical and therapeutical data.   105 
Ethics 106 
All patients signed consent forms to participate in the Icona Foundation Study, in accordance with the 107 
ethical standards of the committee on human experimentation and the Helsinki Declaration (1983 108 
revision). 109 
 110 
Patients enrolled in the ICONA Foundation cohort were included in the present analysis if: 111 
 they had begun cART while naïve to antiretrovirals, from 1st January 1997 or later;  112 
 they had at least 1 TRG and HDL-cholesterol fasting value before baseline, which was defined 113 
as cART initiation; 114 
 they had a baseline fasting blood glucose <=126 mg/dl (7 mmol/l);  115 
 they were never  exposed to anti-diabetic or lipid lowering drugs before baseline; 116 
 they had no diagnosis of DM prior cART initiation;  117 
 118 
DM was defined as two consecutive blood glucose values of >126 mg/dl (7 mmol/l), clinical diagnosis 119 
of DM, or start of anti-diabetes treatment.  Incidence rate of DM was calculated as number of observed 120 
cases of DM subsequent to cART initiation divided by person years of follow-up (PYFU).  Follow-up 121 
period began at commencement of cART  and lasted until onset of DM, death or lost to follow up, 122 
whichever occurred first.  123 
 124 
 125 
 126 
  
 127 
Univariable and multivariable Poisson regression models were fitted, to assess factors associated with 128 
post-cART DM development. Crude risk ratios (RR) were estimated for the following: 129 
- fixed covariates: gender, mode of HIV infection, nationality, years of infection, nadir CD4 cell/mmc,  130 
- covariates at cART start: age, CDC stage, CD4 and log10 HIV-RNA, HCV and HBV co-infection, 131 
total cholesterol and triglycerides, TRG/HDL, 132 
- time-dependent covariates that could change value over the course of the observation period and 133 
which included all consecutive values of each single variable during the follow-up and which were 134 
called follow-up (FU) variables in the text: BMI, total cholesterol, triglycerides, TRG/HDL, type of 135 
antiretroviral regimen, type of backbone combination and type of third drug in the regimen, alcohol 136 
use and FIB4.   137 
 138 
.Patients were pooled according to TRG values at baseline and during follow up:  139 
 ≤ 180 mg/dl (normal TRG)  140 
 181 mg/dl <TRG <300 mg/dl (mild hypertriglyceridemia) 141 
 TRG >300 mg/dl (moderate/severe hypertriglyceridemia) 142 
 143 
Liver fibrosis was evaluated using Fibrosis-4 (FIB-4) score, calculated as:  144 
(Age x AST ) / ( Platelets x ( sqr ( ALT ) ) 145 
and divided up into 3 categories, as follows: 20,21 146 
 FIB4 value>3.25 as a proxy for advanced fibrosis; 147 
 FIB4 value between 1.45 and 3.25 for which fibrosis status is considered to be undetermined; 148 
 FIB4 value<1.45 considered to be absence of advanced fibrosis. 149 
 150 
 151 
Two different multivariable Poisson regression models were fitted, including all factors associated 152 
with p-values of < 0.2 at univariable analysis. An initial model included time-updated values of 153 
TRG/HDL, expressed as follow-up FU-TRG/HDL (model A); a second model included time-updated 154 
values of TRG, expressed as follow-up FU-TRG (model B).  155 
 156 
  
RESULTS 157 
Of the 3,546 patients included in our analysis, 80 developed DM over 13,911 PYFU, representing an 158 
incidence rate of 5.7 per 1,000 PYFU (95%CI4.6-7.1). Most patients were males (73.7%), and their 159 
median age was 38 years (IQR 33-45). Median BMI at baseline was 23.1 (IQR 21.1-25.2), and 22.1% 160 
of patients tested positive for hepatitis C virus antibodies (HCV-Ab). At baseline most patients (82.6%) 161 
had normal triglyceride levels, normal HDL (73% of sample) and median TRG/HDL ratio was 2.8 162 
(IQR 1.8-4.5). Complete patients' characteristics are depicted in Table 1.  163 
During follow-up, 28562 TRG/HDL values were calculated. FU-TRG/HDL ratios affected DM 164 
incidence rate: 1.8/1,000 PYFU (95%CI 0.8-4.0) for subjects with ratios lower than first quartile 165 
(TRG/HDL ratio 0-1.69), 3.9/1,000 PYFU (95%CI 2.2-6.8) for ratios between first and second quartile 166 
(TRG/HDL ratio 1.7-2.69), 5.6/1,000 PYFU (95%CI 3.5-9.0) for ratios between  second and third 167 
quartile (TRG/HDL ratio 2.7-4.5) and  9.8/1,000 PYFU (95%CI 6.8-14.0) for ratios above third 168 
quartile (TRG/HDL ratio>4.5) (figure 1). 169 
FU-FIB-4 score was also associated with increased DM incidence: 3.7/1,000 PYFU (95%CI 2.7-5.0) 170 
for subjects with FIB-4 scores of <1.5, 11.4/1,000 PYFU (95%CI 7.5-17.4) for scores between 1.5 and 171 
3.25 and 16.8/1,000 PYFU (95%CI 8.4-33.6) for FIB-4 of >3.25. 172 
At univariable analysis, abnormal values (181-300 mg/dl and >300 mg/dl) of basal TRG  as well as 173 
time-updated values (FU-TRG) were significantly associated with higher risk of Diabetes' onset, 174 
compared to normal values (≤180 mg/dl). Patients with mild (TRG between 181-300) and 175 
moderate/severe hypertriglyceridemia (TRG>300) at baseline had RR=4.16 ( 95%CI 2.62-6.62, 176 
p<0.001) and RR=2.78  (95%CI 1.18-6.52, p=0.019) respectively, versus patients with normal values.   177 
Similarly, patients with FU-TRG in the mild and moderate/severe groups were at higher risk of DM, 178 
RR=1.83 (95%CI 1.07-3.13, p<0.05) and RR=3.55 (95%CI 2.01-6.28, p<0.001) respectively, 179 
compared to subjects with normal values.  180 
Additionally, higher TRG/HDL ratio values, both at baseline and during follow-up, were associated 181 
with higher risk of new Diabetes' diagnosis, with RR= 1.16 per 10 points higher (95%CI 1.06-1.27, p= 182 
0.001) and RR= 1.18 ( 95%CI 1.10-1.26 , p<0.001) respectively. 183 
At univariable analysis, the following risk factors were found to be associated with higher risk of DM: 184 
higher age, male gender, nadir CD4<200 cells/mm3, CDC C stage versus stage A/B, HCV-Ab positive 185 
  
versus negative, baseline cholesterol between 200 and 240 mg/dL versus normal value ≤200, FU-BMI 186 
between 25 and 29.9 and  FU-BMI≥30 versus FU-BMI<25,  Use of stavudine  plus lamivudine  in 187 
current regimen versus tenofovir plus emtricitabine, Indinavir / IDV-ritonavir use in current regimen 188 
versus efavirenz, FU-FIB-4 score (FIB-4) between 1.5 and 3.25 or >3.25 versus. <1.5. (full results in 189 
Table 2) 190 
Multivariable analysis (model A and model B) is shown in table 2.  The two models differed by the 191 
way FU TRG was modeled: model A included FU-TRG/HDL ratio, while model B included FU-TRG. 192 
In model A higher FU TRG/HDL ratio was associated with higher risk of DM, independently of all 193 
factors included and of FU FIB-4 value. Other factors independently associated with higher risk of  194 
diabetes' onset were:  older age (per 10 year older, RR 1.44; 95%CI 1.06-1.95), p<0.05), FU-BMI>30 195 
(4.92; 95%CI 2.42-10.00 versus BMI<25, p<0.001), use of stavudine+lamivudine in FU-regimens 196 
(6.31; 95%CI 1.95-20.40 versus tenofovir +emtricitabine, p<0.01), use of atazanavir/ritonavir (3.23; 197 
95%CI 1.30-7.98 versus efavirenz, p<0.05), higher FU-TRG/HDL ratios (per 10 points higher 1.63;  198 
95%CI 1.32-2.01, p<0.001), basaline cholesterol between 201-239 mg/dl (2.49; 95%CI 1.30-4.78 199 
versus <=200, p<0.05), and FU- FIB-4>3.25 (2.91: 95%CI 1.10-7.72 versus<1.5, p<0.05). 200 
Additionally, advanced liver fibrosis (defined as FIB-4 index >3.25) was independently associated 201 
with higher risk of DM, particularly in model A, with only marginal association evident in model B 202 
(Table 2). Of note, this association was much stronger among patients without HCV co-infection 203 
(RR 5.28; 95%CI 1.25-22.27) than in those with positive HCV-Ab (RR 1.91; 95%CI 0.61-6.0 p-204 
value for interaction=0.02).  In a multivariate model excluding FIB-4, HCV-Ab positivity was 205 
independently associated with DM development, confirming a strong interaction between FIB-4 and 206 
HCV  (data not shown).  207 
We also explored the risk of diabetes when high values of TRG/HDL and FIB-4 were coexisting and 208 
we found that in patients with a TRG/HDL ≥4.5 (III quartile) and a FIB-4 >3.25 the RR of diabetes 209 
was 4.03 versus those with TRG/HDL<4.5 and FIB-4<1.5 (95%CI 0.86-19.03; p=0.08) confirming a 210 
cumulative effect of the two different markers even if this does not reach a statistical significance. The 211 
interaction test between TRG/HDL and FIB-4 score was not significant (p=0.33)..  212 
  
 213 
  
DISCUSSION 214 
Our primary goal was to evaluate the incidence and determinants of diabetes in a large cohort of 215 
previously antiretroviral treatment-naive patients initiating cART in Italy. In this cohort, incidence of 216 
new-onset diabetes was as high as 5.7 per 1,000 PYFU, not significantly higher than the incidence 217 
reported for uninfected subjects in Italy.22,23  Comparing our data with those obtained from other large 218 
cohorts of HIV-infected subjects, we found that our findings were very similar to incidences found in 219 
the DAD8 and Swiss HIV cohorts,6 but lower than the one reported from the ANRS study.5 The 220 
discrepancy between our findings and those of the French study may be attributable to several factors.  221 
There were significant age disparities between the two populations: nearly 70% of patients in the 222 
French study were over 40 years of age, while median age in our population was 38 years.  Also, in 223 
our analysis only 37% had started cART before 2005, while the French cohort included patients 224 
initiating cART between 1997 and 1999. Such differences in calendar year of inclusion could be an 225 
important variable, translating into into exposure to different antiretrovirals regimes.  For example, in 226 
the French study, new-onset diabetes peak in 1999-2000 and subsequent marked decrease is likely to 227 
be related to exposure to first-generation antiretrovirals. 228 
In our study, we did not have a control group of HIV-negative subjects; however, the incidence of 229 
diabetes we observed in this large cohort of HIV-infected patients was similar to the incidence reported 230 
in a sample of HIV-negative subjects of the same age in northern Italy (5.7 vs. 5.8 per 1,000 PYFU).22 231 
Studies conducted in the U.S.A. produced conflicting results when comparing HIV-infected patients 232 
with HIV-uninfected controls. In the Multicenter AIDS cohort study (MACS), Brown TT et al.4 233 
reported a significantly higher incidence of diabetes in HIV-infected males on cART compared to 234 
HIV-negative males. In contrast, the incidence of diabetes in HIV-infected women in the Women’s 235 
Interagency Study, undertaken by Tien et al.7 was significantly lower than that of the MACS study, 236 
with no observable differences seen between HIV-infected and HIV-uninfected women.  It should be 237 
noted, however, that, each of these studies used a different definition for diabetes; only Tien’s study,7 238 
as ours, used the American Diabetes’ Association guidelines criteria for definition of DM.    239 
Aiming to define independent predictors of new-onset diabetes, we have found that TRG levels and 240 
TRG/HDL ratios in our cohort are predictive of subsequent diabetes in patients initiating cART.  This 241 
is consistent with data obtained in general population for overweight individuals,24since high 242 
prevalence of insulin resistance in subjects with BMI>25 usually determines increases in TRG levels, 243 
and a proportional decrease in HDL.25  Importantly, in our  study, more than half of patients had a 244 
  
normal BMI, allowing us to confirm the usefulness of TRG/HDL ratio in predicting diabetes, even in 245 
non-overweight HIV-infected patients.  246 
One explanation for the association between TRG/HDL ratio and development of diabetes in HIV-247 
infected patients could be that dyslipidemia and/or insulin resistance are involved in the pathogenesis 248 
of type 2 diabetes, paralleling data obtained in the general population.23,26  Indeed, several reports have 249 
suggested that dyslipidemia, in particular high TRG and low HDL levels, play a role in the 250 
development of diabetes in HIV negative patients.27-29 Lipotoxicity, inflammation and endoplasmic 251 
reticulum stress are the three pathogenetic mechanisms which have been postulated to explain this 252 
association 30-32 and maintaining healthy HDL-c levels has recently been proposed as a means of 253 
preventing diabetes 33. 254 
In HIV+ positive patients, the relation between HIV replication, chronic subclinical inflammation and 255 
use of cART may enhance the link between dyslipidemia and diabetes, and thus needs to be 256 
investigated. Vu et al.15 recently demonstrated that the inverse correlation between TRG and HDL-c 257 
found in general population is not present in the HIV population. In determining these results, the 258 
authors took into account CD4 count and detectable viral load, both of which are possible factors 259 
affecting the correlation between HDL-c and TRG. Moreover, the authors showed that HIV patients 260 
possess a unique cholesteryl ester transfer protein (CETP) mass, as well as specific activity. With these 261 
factors in mind, our study may prove to be a useful tool in confirming an association -  already well-262 
defined in general population -  that  merits further investigation in HIV infected patients on cART, 263 
due to the unique characteristics of this population.   264 
The introduction of ART determines an increase in all the lipid profile setting values, comparable to, 265 
or much higher than, those observed prior to HIV-infection.16  The role of ART in the development of 266 
dyslipidemia is therefore of great significance.  For these reasons, and because of the low BMI seen in 267 
the majority of HIV+ patients with or without lipoatrophy,14 our finding that TRG/HDL ratio is 268 
predictive of DM, independently of BMI, is of great significance, and justifies screening for diabetes 269 
in HIV-infected patients with high TRG and TRG/HDL ratio.  270 
Another important concern highlighted by our findings is the optimal cut-off for TRG/HDL ratio in 271 
HIV-infected patients. A significant cut-off of TRG/HDL has been proposed in general population 272 
(>3), which has been demonstrated to be effective in overweight subjects.24 In our study we found a 273 
significantly higher incidence of new-onset diabetes for patients in the third quartile for TRG/HDL 274 
ratio, corresponding to a ratio-value of  >4.5 with a sensitivity of 45.3% and a specificity of 75%. 275 
  
Considering a cut-off =3.5 sensitivity was higher (62.5%) and specificity was reduced (64.1%)  (data 276 
not shown).  Therefore, we could argue that a cut-off of 4.5 should be used for the HIV population, 277 
especially in patients with a normal BMI.  278 
The relation between type of cART, dyslipidemia and incidence of diabetes is a major issue for the 279 
management of HIV-patients. We found a strong association between new-onset of DM and exposure 280 
to ART, especially with stavudine and indinavir use, consistent with the proven ability of these drugs 281 
to induce insulin resistance.5,6 The association we found with atazanavir is difficult to explain. It did 282 
not change even after correcting for atazanavir in first regimen or as a switch.  It may reflect the PI-283 
class effect, and the wide use of Atazanavir in recent years, especially among patients with metabolic 284 
complications.  285 
Our study also explored the predictive value of a liver fibrosis marker (FIB-4) in detecting patients at 286 
risk of DM.  In general population, advanced liver fibrosis (defined as FIB-4 index >3.25) has been 287 
associated with diabetes, due to the high prevalence of non-alcoholic fatty liver disease (NAFLD) in 288 
diabetic patients and drug-induced steatosis.17,18 FIB 4 has therefore been proposed as an indirect 289 
marker correlating with progressive metabolic alterations. 290 
In our cohort, a value of FIB-4 >3.25 was significantly associated with new-onset DM in HCV-Ab 291 
negative subjects; furthermore a strong interaction was found between FIB-4 and HCV, as expected. 292 
Hepatic fibrosis could be a marker of increased risk of diabetes both for metabolic steatosis and for 293 
viral steatosis due to HCV. The association between HCV and diabetes is well described in literature. 294 
34,35 Together with TRG/HDL ratio, FIB-4 >3.25 could therefore prove to be a useful tool for 295 
identifying patients with hepatic damage caused both  by metabolic and HCV-induced steatosis.  296 
Our study presents some limitations. We did not collect waist circumference that could allow us to 297 
evaluate the prevalence of metabolic syndrome in our cohort. Waist circumference is a valid marker 298 
of diabetes’risk and could add important informations at our results. On the other hand we focused our 299 
attention on a surrogate marker of insulin Resistance (TRG/HDL ratio) that is considered the driving 300 
force of metabolic syndrome components. Another limit was the lack of data regarding to HCV-RNA 301 
positivity in patients with HCV-Ab positivity that should have provided the exact prevalence of HCV-302 
related damage. However we did not consider HCV role in our conclusions because of this limit. Our 303 
analysis is on an observational study and can’t provide the strength to define a real causality between 304 
the risk factors and development of diabetes, especially regarding to the associations with ART 305 
regimens 306 
  
In conclusion, in studying a cohort of HIV-infected patients previously naïve to antiretroviral 307 
treatment, we found that incidence of diabetes was more frequent in subjects with lipid abnormalities, 308 
with or without high BMI.  TRG/HDL ratio proved to be an independent predictor of diabetes and thus 309 
a simple and useful marker to identify patients with insulin resistance who are at subsequent risk of 310 
diabetes, in order to enact early prevention strategies. High triglycerides levels observed during cART 311 
are likely to be not only a consequence of therapy, but an effective marker of insulin resistance, even 312 
in presence of normal BMI.  Moreover, measurement of liver fibrosis by FIB-4 could  be of use as a 313 
supplemental DM surrogate marker.   314 
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 463 
Legend to Figure 1:  464 
  
FU (follow-up), TRG (Triglycerides),  FIB-4 (Fibrosis-4 score), HDL (High Density Lipoproteins 465 
Cholesterol), PYFU (Person years of follow-up).   466 
  
Table 1 Study population characteristics N=3546 
Male gender, n (%)  2612 (73.7%) 
Age, years, median (IQR)  38 (33-45) 
Mode of HIV transmission  
    Heterosexual contact 1513 (42.7%) 
    MSM 1224 (34.5%) 
    IVDU 598 (16.9%) 
    Other/unknown 211 (6.0%) 
Italian nationality, n(%) 3045 (85.9%) 
Duration of HIV infection, years, median (IQR)  1.5 (0.2-5.6) 
CDC stage C, n(%) 355 (10.0%) 
Nadir CD4 cells/mm3, median (IQR) 
     <200 cells/mmc, n(%) 
270 (170-361) 
1051 (29.6%) 
Baseline CD4 cells/mm3, median (IQR) 286 (181-384) 
Baseline log10 HIV-RNA copies/ml, median (IQR) 4.8 (4.2-5.2) 
HCV positivity, n(%) 766 (22.1%) 
HBV positivity, n(%) 159 (4.5%) 
Baseline BMI, n(%)  
    <25 kg/cm2 1875 (52.9%) 
    25-29.99 kg/cm2 588 (16.6%) 
     >=30 kg/cm2 131 (3.7%) 
     Unknown 952 (26.8%) 
Baseline total cholesterol, n(%)  
     <200 mg/dl 2943 (83.0%) 
     201-239 mg/dl 423 (11.9%) 
     >=240 mg/dl 104 (2.9%) 
     Unknown 76 (2.1%) 
Baseline HDL cholesterol <35 mg/dl, n(%)  957 (27.0%) 
Baseline triglycerydes, n(%)   
     <=180 mg/dl 2929 (82.6%) 
     181-300 mg/dl 489 (13.8%) 
     >300 mg/dl 128 (3.6%) 
Baseline triglycerides/HDL cholesterol ratio, median (IQR) 2.79 (IQR 1.76-4.53) 
Baseline FIB4 score, median (IQR) 0.87 (0.62-1.28) 
First ARV regimen 
     NRTIs+NNRTI 
     NRTIs+PI/r 
     NRTIs+PI 
     Only NRTIs 
     Other 
 
1486 (41.9%) 
1467 (41.4%) 
329 (9.3%) 
137 (3.9%) 
127 (3.6%) 
Years of cART start 
1997-2001 
2002-2005 
2006-2009 
2010-2014 
 
602 (17.0%) 
754 (21.3%) 
758 (21.4%) 
1432 (40.4%) 
 467 
  
Legend to the table: IQR (Interquartile range), MSM (Men having sex with men), IVDU Intravenous 468 
Drug Users),  CDC (Centers for Disease Control and Prevention), HCV (Hepatitis C Virus Antibodies), 469 
HBV (Hepatitis B Virus Antibodies), BMI (Body Mass Index), HDL (High Density Lipoproteins 470 
Cholesterol), NRTI (nucleoside reverse transcriptase inhibitors),  NNRTI (non- nucleoside reverse 471 
transcriptase inhibitors), PI (Protease Inhibitors), FU (follow-up), FIB-4 (Fibrosis-4 score).  472 
 473 
  
Table 2 Univariate and Multivariate models 474 
 Univariable Multivariable - Model A Multivariable - Model B 
 RR 95% CI P ARR 95% CI P ARR 95% CI P 
Male gender vs female 2.42 1.31-4.47 0.005 2.09 0.91- 4.79 0.083 1.71 0.85- 3.46 0.136 
Age (per 10 yrs older) 1.89 1.55-2.30 <0.001 1.44 1.06- 1.95 0.019 1.64 1.26- 2.13 0.000 
Italian vs not Italian 2.00 0.73-5.47 0.176 1.10 0.29- 4.26 0.887 0.69 0.24- 1.99 0.488 
Nadir cd4 <=200 cells/mmc  2.06 1.31-3.21 0.002 1.16 0.87- 1.54 0.320 1.14 0.89- 1.47 0.304 
CDC stage C vs A/B 2.23 1.32-3.77 0.003 1.18 0.54- 2.59 0.676 1.40 0.73- 2.70 0.315 
HIV-RNA al basale, log10 copies/mL 
(per 1 log higher) 1.22 0.92-1.63 0.173 1.09 0.79- 1.52 0.599 1.10 0.82- 1.48 0.527 
HCV-Ab positive vs negative 1.62 1.01-2.60 0.047 1.70 0.88- 3.25 0.112 1.90 1.07- 3.36 0.028 
Baseline cholesterol, mg/dL                  
  <=200 1.00    1.00     1.00    
  201-239 1.98 1.15-3.41 0.014 2.49 1.30- 4.78 0.006 1.82 0.99- 3.35 0.054 
  >=240 1.01 0.25-4.15 0.988 0.80 0.11- 5.98 0.832 1.09 0.26- 4.58 0.909 
FU-TRG/HDL 
(per 10 points higher) 1.18 1.10-1.26 <0.001 1.63 1.32- 2.01 <0.001       
FU-TRG, mg/dL                
   <180 1.00       1.00    
   180-300 1.83 1.07-3.13 0.027     1.67 0.93- 2.98 0.086 
   >=300 3.55 2.01-6.28 <0.001     2.35 1.19- 4.66 0.014 
FU-BMI                
  <25 kg/cm2 1.00    1.00     1.00    
  25-29.99 kg/cm2 2.36 1.38-4.02 0.002 1.64 0.87- 3.10 0.126 1.99 1.13- 3.51 0.017 
  >=30 kg/cm2 6.76 3.78-12.10 <0.001 4.92 2.42- 10.00 <0.001 5.51 2.83- 10.71 <0.001 
FU- FIB-4 score                   
  <1.5 1.00    1.00     1.00    
  1.5-3.25 3.12 1.84-5.27 <0.001 1.97 1.01- 3.87 0.048 1.72 0.92- 3.19 0.088 
   >3.25 4.58 2.14-9.81 <0.001 2.91 1.10- 7.72 0.031 2.38 0.92- 6.19 0.074 
NRTIs in the current regimen                   
  Tenofovir + emtricitabine 1.00    1.00     1.00    
  Tenofovir + lamivudine 0.92 0.28-3.07 0.896 1.37 0.37- 5.07 0.639 1.32 0.36- 4.81 0.679 
  
  Abacavir + lamivudine 1.10 0.42-2.89 0.847 1.13 0.32- 3.98 0.850 1.43 0.47- 4.38 0.529 
  Zidovudine + lamivudine 1.39 0.77-2.54 0.277 2.16 0.84- 5.54 0.110 1.83 0.75- 4.49 0.184 
  Stavudine + lamivudine 3.92 1.82-8.48 0.001 6.31 1.95- 20.40 0.002 4.48 1.52- 13.24 0.007 
  Didanosine + lamivudine 2.55 0.88-7.37 0.084 2.09 0.44- 9.90 0.352 2.74 0.74- 10.21 0.132 
  Other  1.99 1.05-3.77 0.034 2.38 0.65- 8.63 0.189 3.29 1.09- 9.95 0.035 
Third drug in the current regimen                 
  Efavirenz 1.00    1.00     1.00    
  Nevirapine 0.93 0.39-2.19 0.863 1.19 0.42- 3.33 0.745 0.87 0.33- 2.34 0.790 
  Lopinavir/ritonavir 1.81 0.92-3.59 0.087 1.20 0.47- 3.10 0.702 1.12 0.48- 2.65 0.788 
  Atazanavir/ritonavir 1.55 0.74-3.24 0.240 3.23 1.30- 7.98 0.011 2.40 1.03- 5.63 0.043 
  Fosamprenavir/ritonavir 0.87 0.12-6.47 0.890 1.53 0.19- 12.40 0.692 1.35 0.17- 10.69 0.776 
  Indinavir ± ritonavir 3.13 1.26-7.79 0.014 1.25 0.26- 6.16 0.780 1.54 0.54- 4.44 0.422 
  Saquinavir ± ritonavir 3.23 0.76-13.83 0.114 - -  0.999 3.55 0.76- 16.62 0.108 
  Nelfinavir 1.35 0.40-4.55 0.626 1.59 0.34- 7.37 0.557 1.56 0.43- 5.64 0.497 
  Only NRTI 1.73 0.79-3.81 0.171 1.51 0.39- 5.86 0.552 0.90 0.28- 2.89 0.857 
  Other 0.97 0.41-2.29 0.943 0.95 0.29- 3.15 0.931 0.72 0.24- 2.19 0.567 
Calendar year of cART start  
(per 1 yr more) 0.95 0.90-1.01 0.099 1.02 0.92- 1.14 0.689 1.00 0.91- 1.10 0.956 
Legend to the table: RR (Relative Risk), ARR (Adjusted Relative Risk),  HCV-Ab (Hepatitis C Virus Antibodies), FU (follow-up), TRG 475 
(Triglycerides),  FIB-4 (Fibrosis-4 score),HCV (Hepatitis C Virus Antibodies), HBV (Hepatitis B Virus Antibodies), BMI (Body Mass Index), 476 
HDL (High Density Lipoproteins Cholesterol), NRTI (nucleoside reverse transcriptase inhibitors),  NNRTI (non- nucleoside reverse transcriptase 477 
inhibitors), PI (Protease Inhibitors), FU (follow-up),. 478 
 479 
 480 
